- Home
- RBKB vs IFRX Comparison
RBKB vs IFRX Comparison
Compare RBKB & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBKB
- IFRX
- Stock Information
- Founded
- RBKB 1860
- IFRX 2007
- Country
- RBKB United States
- IFRX Germany
- Employees
- RBKB N/A
- IFRX N/A
- Industry
- RBKB Banks
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- RBKB Finance
- IFRX Health Care
- Exchange
- RBKB Nasdaq
- IFRX Nasdaq
- Market Cap
- RBKB 111.3M
- IFRX 117.8M
- IPO Year
- RBKB 2019
- IFRX 2017
- Fundamental
- Price
- RBKB $10.40
- IFRX $1.05
- Analyst Decision
- RBKB
- IFRX Strong Buy
- Analyst Count
- RBKB 0
- IFRX 2
- Target Price
- RBKB N/A
- IFRX $9.00
- AVG Volume (30 Days)
- RBKB 4.9K
- IFRX 356.5K
- Earning Date
- RBKB 04-24-2025
- IFRX 03-20-2025
- Dividend Yield
- RBKB N/A
- IFRX N/A
- EPS Growth
- RBKB N/A
- IFRX N/A
- EPS
- RBKB N/A
- IFRX N/A
- Revenue
- RBKB $25,911,000.00
- IFRX $171,642.00
- Revenue This Year
- RBKB N/A
- IFRX $381.73
- Revenue Next Year
- RBKB N/A
- IFRX $2,277.23
- P/E Ratio
- RBKB N/A
- IFRX N/A
- Revenue Growth
- RBKB N/A
- IFRX 162.79
- 52 Week Low
- RBKB $7.30
- IFRX $1.01
- 52 Week High
- RBKB $10.50
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- RBKB 56.45
- IFRX 31.57
- Support Level
- RBKB $9.72
- IFRX $1.16
- Resistance Level
- RBKB $10.45
- IFRX $1.30
- Average True Range (ATR)
- RBKB 0.16
- IFRX 0.12
- MACD
- RBKB -0.04
- IFRX 0.02
- Stochastic Oscillator
- RBKB 87.26
- IFRX 9.76
About RBKB Rhinebeck Bancorp Inc.
Rhinebeck Bancorp Inc is the holding company for Rhinebeck Bank which provides a full range of banking and financial services to consumer and commercial customers. Financial services, including investment advisory and financial product sales, are offered through a division of the Bank doing business as Rhinebeck Asset Management (RAM). The Bank's primary business activity is accepting deposits from the general public and using those funds to originate indirect automobile loans (automobile loans referred by automobile dealerships), commercial real estate loans (which include multi-family real estate loans and commercial construction loans), commercial business loans and one- to four-family residential real estate loans, and to purchase investment securities.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.